Semaglutide for Weight Loss: Names, Types & Genetic Factors

Last reviewed: May 30, 2026

Last updated: May 30, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide prescribed specifically for weight loss is marketed under the brand name Wegovy; when prescribed off-label for diabetes, it is called Ozempic. Both contain the same active compound—a GLP-1 receptor agonist originally developed for type 2 diabetes that increases satiety and slows gastric emptying, reducing caloric intake by an average of 10–15% in clinical studies.

Understanding the differences between branded semaglutide formulations and available alternatives is essential for patients exploring treatment options. PlexusDx emphasizes precision wellness by helping you evaluate not only medication names and cost, but also genetic predispositions in peptide pathways and clinical indicators that may influence how your body responds to semaglutide therapy.

Branded Semaglutide Names and FDA Approval Status

Wegovy is the FDA-approved branded semaglutide injection formulated specifically for chronic weight management in adults with obesity or overweight with weight-related conditions. Ozempic, also FDA-approved by Novo Nordisk, is indicated for type 2 diabetes but is frequently prescribed off-label for weight loss due to clinical efficacy data and patient demand.

A third option, Rybelsus, is an oral semaglutide tablet approved for diabetes management. Off-label oral semaglutide use for weight loss has gained clinical interest, though branded oral options remain limited. Both branded and compounded formulations exist in the current market, each with different regulatory pathways and cost implications.

Branded vs. Compounded Semaglutide: What Patients Should Know

Branded semaglutide (Wegovy, Ozempic) undergoes FDA manufacturing oversight and standardized dosing protocols. Compounded semaglutide is prepared by licensed 503A compounding pharmacies and tailored to individual patient needs, often at lower out-of-pocket cost. Both routes require a valid prescription and ongoing provider supervision.

Characteristic	Branded Semaglutide	Compounded Semaglutide
Regulatory pathway	FDA-approved, mass-manufactured	Licensed 503A compounding pharmacy
Typical monthly cost	$900–$1,400+	$149
Dose customization	Fixed strength options	Tailored dosing per provider
Availability	Pharmacy supply-dependent	Often more accessible
Clinical oversight	Standard protocol	Individualized provider-guided

How Genetic Predispositions Inform Semaglutide Selection

Genetic variation in GLP-1 receptor pathways, FTO gene expression, and MC4R signaling can influence individual weight metabolism and potential response patterns to semaglutide. Specific variants (FTO rs9939609, MC4R rs17782313) may provide context about metabolic predispositions and appetite regulation capacity in peptide-responsive pathways.

PlexusDx's Precision Peptide Genetic Test reveals predispositions in these pathways, which may help provide context for provider discussions about medication selection and expected response timelines. These insights do not predict exact medication response but can support a more personalized conversation with your healthcare provider about whether semaglutide aligns with your genetic metabolic profile.

Medical Eligibility, Safety Considerations, and Provider Guidance

Semaglutide is indicated for adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related conditions (hypertension, type 2 diabetes, cardiovascular disease). Contraindications include personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2. Pregnancy is contraindicated; discontinuation is recommended before conception.

Common side effects include nausea, vomiting, constipation, and abdominal discomfort, typically mild and transient. Serious but rare risks include pancreatitis and gallbladder disease. A qualified healthcare provider should evaluate your medical history, current medications, and treatment goals before initiating semaglutide therapy. Regular follow-up monitoring ensures safety and optimal dosing.

How PlexusDx Supports a More Personalized Approach

PlexusDx offers compounded semaglutide injections ($189/mo) and oral semaglutide formulations ($289/mo) prepared by licensed 503A compounding pharmacies, providing accessible alternatives to branded options while maintaining clinical standards and provider oversight. These compounded formulations may help provide cost-effective precision wellness support when evaluated alongside your genetic and clinical profile.

The Precision Peptide Genetic Test ($298) examines key variants in GIPR and FTO, and MC4R genes that reflect predispositions in peptide metabolic pathways. Understanding these pathways may help inform whether GLP-1 agonist therapy aligns with your metabolic genetics, though genetic predisposition does not guarantee exact medication response and should be interpreted with your qualified healthcare provider.

Combining genetic insights with cost-effective compounded medication access and structured provider communication may support a more informed, personalized treatment decision. Discuss your genetic test results and medication options with your provider to develop a weight management strategy tailored to your unique clinical and genetic context.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Which semaglutide brand does this post identify as the one approved for chronic weight management?

Wegovy. The post identifies Wegovy as the FDA-approved branded semaglutide injection formulated specifically for chronic weight management in adults with obesity, or with overweight plus weight-related conditions. It describes Ozempic as the semaglutide product carrying a type 2 diabetes indication that is frequently prescribed off-label for weight loss. Both contain the same active GLP-1 receptor agonist compound.

Where does Rybelsus fit among the semaglutide products the article describes?

Rybelsus is described in the article as an oral semaglutide tablet approved for diabetes management, not for weight loss. The post notes that off-label oral semaglutide use for weight loss has drawn clinical interest, but that branded oral options remain limited. It is the third branded product the naming section covers, after Wegovy and Ozempic.

What BMI thresholds does the post cite for semaglutide eligibility?

The post cites a BMI of 30 kg/m-squared or higher, or 27 kg/m-squared or higher when a weight-related condition is present. The examples it gives for those conditions are hypertension, type 2 diabetes and cardiovascular disease. It stresses that a qualified provider evaluates medical history, current medications and treatment goals before any semaglutide prescription is written.

How does the branded-versus-compounded table describe the difference in regulatory pathway?

The comparison table lists branded semaglutide as FDA-approved and mass-manufactured, versus compounded semaglutide prepared by a licensed 503A compounding pharmacy. Compounded semaglutide is not an FDA-approved finished product. The same table contrasts fixed strength options against provider-tailored dosing, and standard protocol oversight against individualized provider-guided care. Both routes, the post says, require a valid prescription and ongoing supervision.

Which serious risks does the article list beyond the common gastrointestinal side effects?

Beyond nausea, vomiting, constipation and abdominal discomfort, which the article calls typically mild and transient, it names pancreatitis and gallbladder disease as serious but rare risks. It also lists personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2 as contraindications, and states pregnancy is contraindicated with discontinuation recommended before conception.

Related Reading

• Can Genetic Test Predict Response To Semaglutide For Weight Loss
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Semaglutide For Weight Loss 2

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.